stoxline Quote Chart Rank Option Currency Glossary
  
Carisma Therapeutics, Inc. (CARM)
1.17  -0.07 (-5.65%)    06-12 16:00
Open: 1.23
High: 1.2777
Volume: 150,345
  
Pre. Close: 1.24
Low: 1.14
Market Cap: 49(M)
Technical analysis
2024-06-12 4:20:58 PM
Short term     
Mid term     
Targets 6-month :  1.63 1-year :  1.88
Resists First :  1.4 Second :  1.61
Pivot price 1.25
Supports First :  1.07 Second :  0.89
MAs MA(5) :  1.18 MA(20) :  1.29
MA(100) :  1.93 MA(250) :  3.62
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  44.7 D(3) :  35.4
RSI RSI(14): 38.2
52-week High :  9.76 Low :  1.07
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CARM ] has closed above bottom band by 26.7%. Bollinger Bands are 26.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.28 - 1.29 1.29 - 1.3
Low: 1.12 - 1.13 1.13 - 1.14
Close: 1.16 - 1.17 1.17 - 1.18
Company Description

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

Headline News

Mon, 03 Jun 2024
Short Interest in Carisma Therapeutics, Inc. (NASDAQ:CARM) Decreases By 13.7% - Defense World

Sat, 01 Jun 2024
Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Down 13.7% in May - MarketBeat

Thu, 30 May 2024
Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference - Nasdaq

Thu, 16 May 2024
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting ... - PR Newswire

Sun, 12 May 2024
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results - Simply Wall St

Thu, 09 May 2024
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 42 (M)
Shares Float 23 (M)
Held by Insiders 28.6 (%)
Held by Institutions 39.6 (%)
Shares Short 1,570 (K)
Shares Short P.Month 1,650 (K)
Stock Financials
EPS -1.13
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.25
Profit Margin 0 %
Operating Margin -574.4 %
Return on Assets (ttm) -46.4 %
Return on Equity (ttm) -167.6 %
Qtrly Rev. Growth 4.6 %
Gross Profit (p.s.) 0
Sales Per Share 0.36
EBITDA (p.s.) -1.97
Qtrly Earnings Growth 0 %
Operating Cash Flow -78 (M)
Levered Free Cash Flow -53 (M)
Stock Valuations
PE Ratio -1.05
PEG Ratio 0
Price to Book value 4.5
Price to Sales 3.22
Price to Cash Flow -0.63
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android